The passage of the Affordable Care Act in March 2010 marked the beginning of a dramatic transformation of our nation’s health system.
A lot of people are wondering: just what do these changes mean for HIV services and providers?
If you are asking yourself this question, this webinar will help you get some answers!
Please join the Treatment Access Expansion Project (TAEP), in collaboration with the HIV Prevention Justice Alliance (HIV PJA) and the Coalition for a National AIDS Strategy for this important webinar:
Ryan White and Health Care Reform:
Future Paths for Integration, Expansion, and Innovation
We will describe and discuss major challenges and opportunities presented by
federal health care reform for Ryan White providers, prevention groups and others.
February 10, 2011 @ 12 pm EST / 11 am CT / 10 am MT / 9 am PT
PRE-REGISTER FOR THE CALL
TO RECEIVE CALL-IN / LOG-IN INFORMATION:
We will provide a broad overview of the changing landscape for the Ryan White Program, and the need for providers to start thinking about strategies to ensure that the coordinated and comprehensive services that are the hallmark of the Ryan White Program continue and thrive.
We will also discuss – in broad terms – some of the opportunities presented
by health care reform, including:
- leveraging the community health center expansion initiatives
- utilizing new reimbursement mechanisms and funding streams
- integrating HIV services, including prevention, into broader systems of care
Information will be provided about available resources for providers interested in learning more about the different options and paths discussed.
We will also leave ample time to address comments and questions from participants.
PRE-REGISTER FOR THE CALL
TO RECEIVE CALL-IN / LOG-IN INFORMATION:
This webinar is sponsored by the Treatment Access Expansion Project (taepusa.org), AIDS Foundation of Chicago, HIV Prevention Justice Alliance, and the Coalition for a National AIDS Strategy (nationalaidsstrategy.org). One of many groups supporting the Coalition’s efforts, Bristol-Myers Squibb has generously sponsored this teleconference, with no review or editorial discretion as to topics or content discussed.
